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Background: We examine the epidemiology, natural history, and prognostic factors that
affect the duration of survival for islet cell carcinoma by using population-based registries.
Methods: The Surveillance, Epidemiology, and End Results (SEER) Program database
(1973–2003 release, April 2006) was used to identify cases of islet cell carcinoma by histology
codes and tumor site.
Results: A total of 1310 (619 women and 691 men) cases with a median age of 59 years were
identiﬁed. The annual age-adjusted incidence in the periods covered by SEER 9 (1973–1991),
SEER 13 (1992–1999), and SEER 17 (2000–2003) were .16, .14, and .12 per 100,000,
respectively. The estimated 28-year limited duration prevalence on January 1, 2003, in the
United States was 2705 cases. Classified by SEER stage, localized, regional, and distant stages
corresponded to 14%, 23%, and 54% of cases. The median survival was 38 months. By stage,
median survival for patients with localized, regional, and distant disease were 124 (95% CI,
80–168) months, 70 (95% CI, 54–86) months, and 23 (95% CI, 20–26) months, respectively. By
multivariate Cox proportional modeling, stage (P< .001), primary tumor location (P= .04),
and age at diagnosis (P < .001) were found to be signiﬁcant predictors of survival.
Conclusions: Islet cell carcinomas account for approximately 1.3% of cancers arising in the
pancreas. Most patients have advanced disease at the time of diagnosis. Despite the diseases
reputation of being indolent, survival of patients with advanced disease remains only 2 years.
Development of novel therapeutic approaches is needed.
Key Words: Islet cell—Pancreatic endocrine tumor—Neuroendocrine tumor—Epidemiol-
ogy—Survival.
Islet cell carcinomas are low- to intermediate-grade
neuroendocrine carcinomas of the pancreas. Also
known as pancreatic endocrine tumors or pancreatic
carcinoid, they account for the minority of pancreatic
neoplasms and are generally more indolent than pan-
creatic adenocarcinoma. Islet cell carcinomas, which
arise from islets of Langerhans, can produce insulin,
glucagon, gastrin, and vasoactive intestinal peptide,
causing the characteristic syndromes of insulinoma,
glucagonoma, gastrinoma, and VIPoma. Pancreatic
polypeptide is also frequently produced, yet it is not
associated with a distinct clinically evident syndrome.
Although the molecular biology of sporadic islet
cell carcinoma is less well understood than other
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more common solid tumors, they can arise in con-
nection with several hereditary cancer syndromes.
The best known of these, multiple endocrine neo-
plasia type 1 (MEN1), is an autosomal-dominant
inherited disorder characterized by tumors of the
parathyroids, pituitary, and pancreas.1 Less com-
monly, neuroendocrine (carcinoid) tumors of the
duodenum (gastrinomas), lung, thymus, and stomach
have also been described.2
Tuberous sclerosis and neuroﬁbromatosis are two
other hereditary cancer syndromes associated with
the development of neuroendocrine tumors. TSC1/2
complex inhibits mTOR and is normally expressed in
neuroendocrine cells.3 Patients with a defect in the
TSC2 gene have tuberous sclerosis and are known to
develop islet cell carcinoma.4 Neuroﬁbromatosis is
associated with the development of carcinoid tumors
of the ampulla of Vater, duodenum, and mediasti-
num.5,6 The gene responsible for neuroﬁbromatosis 1
(NF1) regulates the activity of TSC2. The loss of NF1
in neuroﬁbromatosis leads to constitutive mTOR
activation.7 Finally, islet cell carcinomas also occur in
approximately 12% of patients with von Hippel-
Lindau disease (vHL).8 The vHL gene is located on
chromosome 3p26–p25; inactivation of the vHL gene
is thought to stimulate angiogenesis by promoting
increased HIF-1a activity.
Little is known about the epidemiology and natural
history of islet cell carcinoma. Although several case
series have been reported, there have been few pop-
ulation-based studies. This is in part due the
uncommonness of this disease as well as the com-
plexity of its classiﬁcation. Although pancreatic car-
cinoid based on ICD-O-3 histology classiﬁcation
(8240–8245) has been partially described in studies of
carcinoid from the Surveillance, Epidemiology, and
End Results (SEER) Program,9 these have been
incomplete analyses because most islet cell carcino-
mas were coded differently in the ICD-O-3 system
(8150–8155). Survival of patients with islet cell tu-
mors was also described in a recent report on
malignant digestive endocrine tumors that was based
on data from England and Wales.10 In this popula-
tion-based study, we have undertaken a comprehen-
sive analysis of patients with islet cell carcinoma
identiﬁed through the SEER Program database in the
United States.
METHODS
The SEER Program was created as a result of the
National Cancer Act of 1971. The goal of the SEER
Program is to collect data useful in the prevention,
diagnosis, and treatment of cancer. In this study, we
used the SEER data based on the November 2005
submission. For incidence and prevalence analyses,
registry data was linked to total U.S. population data
from 1969 to 2003.11
Since 1973, the SEERProgramhas expanded several
times to improve representative sampling of minority
groups as well as to increase the total sampling of cases
to allow for greater precision. The original SEER 9
registries included Atlanta, Connecticut, Detroit, Ha-
waii, Iowa, New Mexico, San Francisco–Oakland,
Seattle–Puget Sound, and Utah. In 1992, four addi-
tional registries were added to form the SEER 13 reg-
istries, which included the SEER 9 registries, plus Los
Angeles, San Jose–Monterey, rural Georgia, and the
Alaska Native Tumor Registry. More recently, in
2000, data from greater California, Kentucky, Loui-
siana, and New Jersey were added to the SEER 13
Program to form the SEER 17 registries. SEER 9, 13,
and 17 registries cover approximately 9.5%, 13.8%,
and 26.2% of the total U.S. population, respectively.
The data set we use here contains information about a
total of 4,539,680 tumors from 4,123,001 patients
diagnosed from 1973 to 2003.
Islet cell carcinomas were identiﬁed by search for
ICO-O-3 histology codes 8150–8155, 8240–8245, and
pancreatic primary site (duodenal gastrinomas were
excluded). The included histology codes correspond
to the following clinical/histologic diagnoses: islet cell
carcinoma, insulinoma, glucagonoma, gastrinoma,
mixed islet cell/exocrine carcinoma, VIPoma, carci-
noid, enterochromaffin cell carcinoid, and adenocar-
cinoid. The SEER registries include neuroendocrine
neoplasms that are considered invasive and malignant
(behavior code of 2 or 3 in the International Classiﬁ-
cation of Diseases for Oncology, 2nd edition [ICD-O-
2]). Cases designated as poorly differentiated or ana-
plastic were excluded. A total of 1310 cases of islet cell
carcinoma were included in this study. Cases identi-
ﬁed at the time of autopsy or by death certiﬁcate only
were excluded (36 cases) from survival analyses.
Although a tumor, node, metastasis system classi-
ﬁcation system has recently been proposed,12 during
the period of time that we studied, there was no ac-
cepted staging system for islet cell carcinoma. Here,
we use the SEER staging system. Tumors in the
SEER registries were classiﬁed as localized, regional,
or distant. In this system, a localized neoplasm was
deﬁned as an invasive malignant neoplasm conﬁned
entirely to the organ of origin. A regional neoplasm
was deﬁned as a neoplasm that has (1) extended be-
yond the limits of the organ of origin directly into
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surrounding organs or tissue; (2) involves regional
lymph nodes; or (3) fulﬁlls both of the above. A
distant neoplasm was deﬁned as a neoplasm that has
spread to parts of the body remote from the primary
tumor.
The comparisons between patients, tumor charac-
teristics and disease extension were based on the v2
test. One-way analysis of variance was used for the
comparison of continuous variables between groups.
Survival duration was measured by the Kaplan-Meier
method and compared by the log rank test. The sta-
tistical independence between prognostic variables
was evaluated by multivariate analysis by the Cox
proportional hazard model.
SEER*Stat 6.2.4 (Surveillance Research Program,
National Cancer Institute) was used for incidence and
limited-duration prevalence analyses.13 All other
statistical calculations were performed by SPSS 12.0
(Apache Software Foundation 2000). Survival dura-
tions calculated by SPSS were also veriﬁed by parallel
analyses by SEER*Stat. Comparative differences




Between 1973 and 2003, a total of 101,192 pan-
creatic neoplasms in 101,173 patients were identiﬁed
in the SEER 17 registries. Among these, 101,046
neoplasms were classiﬁed as malignant and occurred
in 101,029 patients. When we restricted the search to
codes of neuroendocrine histology, a total of 1385
neoplasms in 1385 patients were identiﬁed. We re-
moved 75 patients who were classiﬁed as having tu-
mors of poorly diﬀerentiated or anaplastic grade.
Thus, a total of 1310 patients had pancreatic islet cell
carcinomas in the SEER registries. This consisted of
1.3% of all patients with pancreatic cancers.
By using linked population ﬁles, we calculated the
incidence of islet cell carcinoma as a rate per 100,000
per year, age-adjusted to year 2000 U.S. standard
population. Because the SEER 9, 13, and 17 registries
were linked to diﬀerent population data sets, we
computed the age-adjusted incidence rates in three
time periods. The age-adjusted incidence in the SEER
9 registries between 1973 and 1991 was .16 per
100,000. For the SEER 13 registries, from 1992 to
1999, an age-adjusted incidence of .14 per 100,000
was observed. Finally, for the period covered by the
SEER 17 registries, from 2000 to 2003, the age-ad-
justed incidence rate was .12 per 100,000. This sug-
gests that on the basis of the current U.S. population
estimate of 302 million, approximately 362 cases of
malignant islet cell carcinoma will be diagnosed each
year. The number of small benign islet cell tumors
may be higher. Detailed incidence data by time per-
iod, sex, and race are included in Table 1.
Limited Duration Prevalence
Among the population sampled by the SEER 9
registries, 28-year limited duration prevalence for islet
cell carcinoma on January 1, 2003, was estimated by
the counting method to be 227 (95% CI, 199–259).
These data were then projected to the general U.S.
population. Data were matched by sex, race, and age
to the U.S. standard population. The estimated 28-
year limited duration prevalence of islet cell carci-
nomas on January 1, 2003, in the United States was
2705 cases. In comparison, the 28-year limited dura-
tion prevalence for all pancreatic neoplasms regard-
less of histology was 27,201.14 Thus, although islet
cell carcinoma represented 1.3% of pancreatic cancer
by incidence, it represented 9.9% of cases by the 28-
year limited duration prevalence analyses.
Patient Characteristics
Of the 1310 patients with islet cell carcinoma
identiﬁed in the SEER database, there were 619 wo-
men and 691 men. The majority (1095 cases) were
TABLE 1. Age-adjusted incidence rate of islet cell carci-
noma per 100,000 populationa
Time period and race All Male Female
SEER 9 (1973–1991)
All races .16 (.15–.18) .19 (.17–.22) .14 (.13–.16)
White .16 (.14–.17) .19 (.16–.21) .14 (.12–.16)
African American .25 (.19–.32) .29 (.19–.43) .22 (.16–.32)
Other .11 (.07–.18) .16 (.09–.28) .08 (.04–.16)
SEER 13 (1992–1999)
All races .14 (.13–.16) .17 (.15–.20) .12 (.10–.14)
White .15 (.13–.17) .18 (.15–.21) .13 (.11–.15)
African American .11 (.07–.16) .12 (.05–.25) .10 (.06–.18)
Other .13 (.09–.18) .18 (.11–.28) .09 (.05–.15)
SEER 17 (2000–2003)
All races .12 (.10–.13) .12 (.11–.15) .11 (.09–.13)
White .12 (.11–.13) .14 (.12–.16) .11 (.09–.13)
African American .14 (.09–.19) .10 (.05–.20) .16 (.10–.24)
Other .07 (.04–.12) .03 (.01–.11) .11 (.06–.18)
aRates are per 100,000 population (95% conﬁdence interval) age-
adjusted to year 2000 U.S. standard population. Cases were se-
lected by ICD-O-3 histology codes 8150–8155, 8240–8245, and
confirmed pancreatic primary site. Cases designated as poorly
differentiated or anaplastic by grade were excluded. Cases of un-
known race are excluded from the ‘‘other’’ category (included in
‘‘all races’’).
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white. African American and other racial groups
accounted for 134 and 78 cases, respectively. Details
of patient characteristics are included in Table 2. The
other racial groups included American Indian/Alas-
kan Natives, and Asian/Paciﬁc Islanders. In three
cases, the race was unknown. We plotted the number
of cases by age group at diagnosis in Fig. 1; the peak
age distribution was 65 to 69 years. However, the
median age at diagnosis was 59 years.
We next examined the eﬀect of race and sex on age
at diagnosis. The median age in years at diagnosis for
white, African American, and other racial groups was
60 (mean 58, SD 14.9), 55 (mean 54.5, SD 16.5) and
56 (mean 57, SD 16.5), respectively (P= .02, Fig. 2).
However, there was no difference in median age at
diagnosis based on sex.
Tumor Location and Hormone Production
The location of the primary tumors within the
pancreas was described in 868 cases. In 442 cases, the
detailed location data is not known. This is partially
because the current coding system allows tumor
location to be coded as islet of Langerhans, which
gives no information about the location of the tumor
within the pancreas. In 379 cases, the primary tumor
was located in the head of the pancreas; body, tail,
and overlapping groups accounted for 103, 278, and
108 cases, respectively.










Median (SD) age at diagnosis (y) 59 (15)
ICD-O-3 groupings, n (%)





Mixed histology 26 (2)











Year of diagnosis, n (%)
1973–1988 482 (37)
1989–2003 828 (63)
a Cases selected from SEER 17 database by ICD-O-3 histology
codes 8150–8155, 8240–8245, and pancreatic primary site. Cases
designated as poorly differentiated or anaplastic by grade were
excluded.
FIG. 1. Age at diagnosis of 1310 cases of islet cell carcinoma. The
median and mean (SD) ages at diagnosis are 59 and 58 (15) years.
FIG. 2. Age at diagnosis by race. White patients were older at the
time of diagnosis (P= .02). The median age at diagnosis for white,
African American, and other racial groups was 60 (mean 58, SD
14.9), 55 (mean 54.5, SD 16.5), and 55.5 (mean 57, SD 16.5),
respectively.
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By ICD-O-3 histology codes, 1117 cases (Table 2)
were coded as islet cell or carcinoid (ICD-O-3 =
8150, 8240, 8241). Because these designations can
include either serotonin-producing or nonfunctional
tumors, it is not possible to determine the secretory
status in these cases. Among the known functional
tumors, gastrinoma was the most common with 73
cases (22 cases of duodenal gastrinoma not included);
insulinoma, glucagonoma, and VIPoma accounted
for 49, 26, and 16 cases, respectively. Finally, in 26
cases, the tumors were considered to have mixed
endocrine/exocrine histology (ICD-O-3 = 8154,
8243–8245).
Next, we compared the location of the primary
tumors within the pancreas by histological classiﬁ-
cation. We found signiﬁcant diﬀerences in the pat-
tern of primary tumor localization (P = .029);
nonfunctional or serotonin-producing tumors (coded
as islet cell and carcinoid tumors) were more likely
to be located in the head (44%) than in the body
(12%) or tail (31%) or overlapping (14%). Among
the functional neoplasms, most insulinomas (57%),
glucagonomas (53%), and VIPomas (64%) were lo-
cated in the tail of the pancreas. Gastrinomas were
much more likely to be located in the head of the
pancreas (63%).
Tumor Stage
Of the 1310 cases, 125 (10%) were not staged
(Table 2). For the remaining 1185 cases, 179 (14%)
were localized; 295 (23%) were classiﬁed as regional;
and 711 (54%) were classiﬁed as distant. When we
compared stage by ICD-O-3 histology, we found that
most carcinomas were metastatic at the time of
diagnosis, including islet cell carcinomas (61%), ins-
ulinomas (61%), glucagonomas (56%), and gastrino-
mas (60%). A smaller percentage of VIPomas (47%)
were metastatic (P < .001). This may be the result of
the presence of massive diarrhea in VIPoma patients,
which may bring them to medical attention earlier.
The higher rate of metastases among insulinoma
patients observed in this study is likely because most
small insulinoma are considered benign and not re-
ported to SEER. Next, we compared stage by tumor
location and found that tumors located at the head of
the pancreas trended toward a lower rate of distant
disease (48% head vs. 57% body, 58% tail, and 60%
overlapping) and a higher rate of regional disease
(34% head vs. 27% body, 23% tail, 27% overlapping).
However, the difference was not statistically signiﬁ-
cant (P = .063).
Survival
For survival analyses, we excluded 36 cases that
were identiﬁed at autopsy or on the basis of death
certiﬁcates only. The median overall survival for all
1274 remaining cases was 38 months (95% CI, 34–43).
When compared by the log rank test, SEER stage
predicted patient outcome (P < .001). The median
survival for patients with localized, regional, and
distant islet cell carcinoma was 124 months, 70
months, and 23 months, respectively (Fig. 3). One-
year, 3-year, 5-year, and 10-year survival rates are
listed in Table 3. The median survival for those cases
that were not staged was 50 (95% CI, 34–66) months.
Relative risk was calculated by Cox proportional
modeling. Compared to the group with localized
disease, patients with regional and distant disease had
1.56- and 3.50-fold of increased risk of death during
the period (1973–2005) included in this study.
We then examined potential prognostic factors for
survival duration that were based on data available
from the SEER database. For these analyses, we
stratiﬁed patients by stage. Patients with missing
stage data were excluded from the analyses. When
compared against the group designated as islet cell or
carcinoid by ICD-O-3 histology codes, patients with
gastrinoma (P = .001) and VIPoma (P = .044) had
longer survival durations after adjusting for the effect
of stage (Table 4), while the group with mixed his-
tology experienced worse survival. The difference was
FIG. 3. Stage and survival of 1157 patients from the time of
diagnosis. Median duration of survival of patients with localized (n
= 167), regional (n = 289), and distant disease (n = 558) was 124,
70, and 23 months, respectively (P < .001).
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not statistically signiﬁcant, which is likely because of
the small number of cases in this category.
The location of the primary tumor may have a
marked eﬀect on the time of presentation (head tu-
mors may obstruct the bile duct and cause visible
jaundice) and resectability, as well as on surgical
morbidity and mortality. Therefore, we next exam-
ined the prognostic role of the location of the primary
tumor within the pancreas (Table 4). In our analyses,
tumors located at the head of the pancreas were less
likely to be associated with distant metastasis. The
rates of distant metastasis for primary tumors located
in the head, body, tail, and overlapping locations
were 48%, 57%, 58%, and 60%, respectively. These
differences were not statistically signiﬁcant (P =
.063). However, once adjusted for stage, primary tu-
mor location in the pancreatic head was associated
with a worse prognosis than the pancreatic body (P
= .037). Similarly, tumors in the pancreatic head
tended to be associated with worse survival compared
with those in the pancreatic tail (P = .056); however,
the difference was not statistically signiﬁcant. Pa-
tients with primary tumors that were classiﬁed as
overlapping had the worst prognosis (P = .041). In
some cases, an overlapping lesion may indicate a
larger primary tumor that covered a larger portion of
the pancreas.
Age is found to be a predictor of outcome in a
variety of malignancies. We examined the eﬀect of
age at diagnosis on overall survival stratiﬁed by stage
(Table 4, Fig. 4). In the Kaplan-Meier analysis, we
separated the patients into two groups on the basis of
median age. We observed decreasing survival with
increasing age (P < .001). Similarly, we also exam-
ined the effect of age as a continuous variable in Cox
proportional hazard modeling and found increasing
age to be a predictor of poor outcome (P < .001).
Next, we examined the survival duration of pa-
tients with islet cell carcinoma by year of diagnosis.
There has been an improvement in survival over time.
Whether analyzed as a continuous variable by Cox
proportional hazard modeling or divided into dis-
crete time durations, the observed diﬀerence was
statistically signiﬁcant (P = .001). Sex and race did
not signiﬁcantly affect survival. The details of these
analyses are included in Table 4.
Finally, we performed multivariate survival analy-
ses by Cox proportional hazard modeling. SEER
stage, primary tumor localization, ICD-O-3 histology
groups, and age at diagnosis were entered into the
model. In multivariate analysis, the ICD-O-3 histol-
ogy group was not a statistically signiﬁcant predictor
of outcome. All other variables retained statistical
signiﬁcance; the most important predictor of outcome
was stage. Compared to patients with localized dis-
ease, patients with regional (HR = 1.44) and distant
(HR= 3.40) disease had decreased survival duration.
Location of the primary tumor within the pancreas (P
= .032) and age at diagnosis (P< .001) also remained
signiﬁcant predictors of outcome (Table 5).
TABLE 3. Survival by SEER stage
SEER stage Median survival (mo) (95% CI)
Survival rate
HR P1 y 5 y 10 y
Local 124 (80–168) 88% 71% 52% 1.00 (referent) <.001
Regional 70 (54–86) 82% 55% 38% 1.56 (1.17–2.07)
Distant 23 (20–26) 65% 23% 9% 3.50 (2.71–4.54)
SEER, Surveillance, Epidemiology, and End Results Program; 95% CI, 95% conﬁdence interval; HR, hazard ratio.
TABLE 4. Cox proportional hazard analyses of potential
prognostic factors adjusted for stagea
Parameter HR (95% CI) P value
ICD-O-3 group
Islet cell 1.00 (referent)
Insulinoma .935 (.64–1.37) .728
Glucagonoma 1.12 (.68–1.84) .652
Gastrinoma .57 (.41–.80) .001
VIPoma .44 (.20–.98) .044
Mixed histology 1.18 (.65–2.13) .596
Location of primary tumor
Head 1.00 (referent)
Body .74 (.55–.98) .037
Tail .82 (.67–1.01) .056
Overlapping 1.32 (1.01–1.72) .041
Age as a continuous variable 1.03 (1.03–1.04) <.001
Age grouped by median
0–59 1.00 (referent)
60+ 2.16 (1.87–2.49) <.001
Sex
Female 1.00 (referent)
Male 1.07 (.93–1.23) .367
Race
African American 1.00 (referent)
White 1.18 (.93–1.50) .176
Other 1.31 (.89–1.92) .173
Year of diagnosis
1973–1988 1.00 (referent)
1989–2003 .79 (.68–.91) .001
aAll analyses have been adjusted for Surveillance, Epidemiology,
and End Results Program stage.
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DISCUSSION
In order for us to make advances in the diagnosis
and management of patients with islet cell carcinoma,
we must improve our understanding of the epidemi-
ology, natural history, and prognostic factors for this
relatively rare disease. Because of the rarity of neu-
roendocrine carcinoma and the lack of a staging
system, much of the information previously pub-
lished has been based on case series and anecdotal
experiences. In this study, we take advantage of the
vast amount of data collected by the SEER Program
to examine the largest series of islet cell carcinomas
reported to date. To our knowledge, this study rep-
resents the only population-based study of islet cell
carcinoma in published literature.
Prevalence is deﬁned as the number people alive on
a certain date in a population that ever had a diag-
nosis of the disease. In this study, the counting
method15 was used to estimate prevalence from inci-
dence and follow-up data obtained from the SEER 9
registries. Complete prevalence can be established by
this method by using registries of very long duration.
The SEER 9 registries have the longest follow-up
duration and contain data suitable for prevalence
analyses for the past 28 years. Given the longer sur-
vival duration often experienced by patients with
neuroendocrine carcinoma, we report only limited
duration prevalence data which may somewhat
underestimate the complete prevalence. By incidence,
islet cell carcinomas account for only 1.3% of all
pancreatic cancers. However, because of the better
outcome generally experienced by patients with islet
cell carcinoma, they represent almost 10% of pan-
creatic cancers in prevalence analyses.
We acknowledge that analyses from the SEER
registries underestimate the total number of patients
with islet cell tumors. All cases from the SEER data-
base were denoted to be malignant. Thus, it is likely
that small, benign-appearing tumors were not in-
cluded in the SEER registries (for example, insulino-
mas and small nonfunctioning tumors). Although
histologic evidence of invasion of basement mem-
brane deﬁnes malignant behavior for most epithelial
malignancies, the deﬁnition of malignant behavior for
pancreatic neuroendocrine neoplasms is more com-
plex. In the absence of malignant behavior such as
direct invasion of adjacent organs, metastases to re-
gional lymph nodes or distant sites, it may be diﬃcult
to classify an islet cell tumor as benign or malignant.
Pancreatic endocrine tumors are classiﬁed as benign,
uncertain malignant potential, and malignant on the
FIG. 4. Age and survival. For the <59 age group, the median survival durations for localized, regional, and distant disease were 282 (95% CI,
204–360) months, 114 (95% CI, 83–145) months, and 35 (28–42) months. For the 60+ age group, the median survival durations for localized,
regional, and distant disease were 46 (95% CI, 20–72) months, 38 (95% CI, 24–52) months, and 13 (95% CI, 10–16) months (P < .001).
TABLE 5. Multivariate survival analyses




Distant 3.40 (2.53–4.67) <.001
Age as a continuous variable 1.03 (1.02–1.04) <.001
Location of primary tumor .032
Head 1.00 (referent)
Body .81 (.60–1.08) .146
Tail .87 (.71–1.07) .175
Overlapping 1.26 (.97–1.65) .089
ICD-O-3 group .186
Islet cell 1.00 (referent)
Insulinoma .80 (.46–1.39) .427
Glucagonoma 1.08 (.57–2.02) .822
Gastrinoma .70 (.47–1.04) .077
VIPoma .39 (.12–1.22) .105
Mixed histology 1.38 (.73–2.59) .322
HR, hazard ratio; 95% CI, 95% conﬁdence interval.
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basis of size, the presence or absence of lymphovas-
cular invasion, and the number of mitoses and Ki-67–
positive cells by immunohistochemistry. However,
there is a considerable overlap among these histo-
pathologic features in benign and malignant neuro-
endocrine tumors and there is even heterogeneity
within different areas of the same tumor. Many small
islet cell tumors may have been considered benign or
of unclear malignant potential and were excluded
from the SEER registries. However, size is likely a
function of when a tumor is diagnosed; left untreated,
it is likely that most islet cell tumors will eventually
grow locally into adjacent structures or soft tissues,
and/or spread to distant organs. Therefore, outside of
small insulinomas, all islet cell neoplasms should be
considered potentially malignant. Thus, although the
SEER registry data provide important information
about malignant islet cell tumors, the extent to which
it underestimates the frequency of smaller islet cell
neoplasms is unknown. In our experience, even small
islet cell tumors without clear evidence of invasion or
metastasis at the time of initial surgical resection may
recur and spread years later.
We found a wide distribution of age at diagnosis,
with a median of 59 years. Separated by race, white
patients were older at the time of diagnosis. When we
compared stage by histologic type, we found that
VIPomas were less likely to be metastatic at the time
of diagnosis. Several ﬁndings may have contributed
to this observation. One possible explanation is that
VIPomas are generally associated with profound
watery diarrhea, which may cause patients to seek
medical attention earlier than if they had nonfunc-
tional tumors. Second, as previously mentioned,
small insulinomas and gastrinomas may have been
considered benign (in the absence of invasion of
adjacent organs, lymph node metastases, or distant
metastases) and therefore not captured for analysis
thereby enriching the population of study patients
with metastatic functioning tumor.
In an earlier publication that was based on data
from the SEER Program, Modlin et al.9 described the
ﬁve-year overall survival of patients with carcinoid
tumors to be 59.5% to 67.2%. The survival of patients
with islet cell carcinoma seems less favorable. In the
present study, we observed a median overall survival
of 38 months. This is identical to the median survival
observed in a large retrospective series of 163 cases
from the University of Texas M. D. Anderson Cancer
Center.16 The survival duration of patients with dis-
tant metastases was also similar (23 months in cur-
rent study vs. 25 months in the M. D. Anderson
series). We did, however, observe improvements in
the outcome of patients with islet cell carcinoma over
time. These improvements were observed among all
SEER stage groups (data not shown), and are likely
due in part to improvements in supportive care.
By multivariate survival analysis, we found that
stage of disease, primary tumor location, and age at
diagnosis were important predictors of outcome. The
diﬀerence in survival by primary tumor location can
be attributed to several possible factors. In this study,
patients with tumors classiﬁed as having overlapping
location had the worst outcome. This is likely because
of the larger tumor size in this group. Tumor located
at the head of pancreas may be diagnosed earlier
because of hyperbilirubinemia resulting from biliary
obstruction. This is suggested by our ﬁnding of a
trend (nonsigniﬁcant) for a lower rate of metastastic
disease at the time of diagnosis on the basis of tumor
location in the pancreatic head. However, adjusted
for stage, patients with a tumor located in the pan-
creatic head were more likely to have a worse out-
come than patients with tumors located in the body
or the tail of the pancreas. One possible explanation
is that tumors arising in the pancreatic head are of
greater malignant potential. For example, most ins-
ulinomas (57%), glucagonomas (53%), and VIPomas
(64%) were located in the tail of the pancreas. Such
functioning tumors were also associated with im-
proved survival compared with nonfunctioning tu-
mors. In addition, the fact that tumors in the
pancreatic head are more likely to cause biliary
obstruction (with a risk for cholangitis), invade the
duodenum (resulting in hemorrhage or obstruction),
or involve the peripancreatic mesenteric vasculature
(resulting in pain, mesenteric foreshortening, and
malabsorption) may contribute to local tumor mor-
bidity which may inﬂuence survival duration. There is
also likely to be a general tendency on the part of
physicians to avoid surgical resection of the pancre-
atic head (pancreaticoduodenectomy or Whipple
procedure) when faced with a large tumor or low
volume metastatic disease. This is not the case with
tumors in the body or tail of the pancreas that can be
surgically excised with a distal pancreatectomy.
However, it is the pancreatic head tumor that carries
the greatest risk for tumor associated morbidity such
as hemorrhage and biliary or gastric outlet obstruc-
tion.16 To what degree patients with pancreatic head
tumors suffer morbidity and mortality from local
disease progression rather than distant metastases
cannot be determined from this data set.
Finally, increasing age at diagnosis was a predictor
of poor outcome in our study. The diﬀerences in
survival were seen across all SEER stage groupings.
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Certainly, pancreatic resection carries considerable
operative risks and the medical comorbidities that are
associated with advancing age may have precluded
some patients from resection while increasing the risk
to those taken to surgery. For patients with advanced
disease, systemic chemotherapy often includes drugs
that are considered toxic.17,18 For example, doxoru-
bicin is recognized to be cardiotoxic, and streptozocin
may cause worsening of diabetes. Thus, heart disease
and diabetes which are more common among older
patients may have limited the use of these drugs.
At present, surgery is the only curative treatment
for islet cell carcinoma. Surgery should be recom-
mended for most patients in whom cross-sectional
imaging suggests that complete resection is possible.19
Although islet cell carcinoma has a better prognosis
than adenocarcinoma of the pancreas, the disease
remains incurable once multifocal unresectable met-
astatic disease exists. Although survival beyond 10
years has been described in the literature for some
patients with metastatic disease, the survival duration
for most with advanced disease is far shorter. Al-
though streptozocin-based chemotherapy can induce
objective response in 32% to 39% of patients,17,20
second-line treatment options are limited. Newer
approaches such as peptide receptor radiotherapy,
systemic agents targeting vascular endothelial growth
factor, and mTOR are under development.
Optimal management of patients with islet cell
carcinoma requires an understanding of the disease
process and a multimodal approach. A better
understanding of the molecular biology of this dis-
ease may lead to improved clinical models for pre-
dicting outcome and developing novel treatment
strategies for this relatively rare but complex disease.
Until then, an understanding of the natural history of
the disease as provided herein is necessary to allow
physicians and patients to accurately assess the risks
and potential beneﬁts of treatment alternatives that
are based on the extent of disease and the age and
performance status of the patient.
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